Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.
Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.
In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:
- Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
- Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
- Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
- Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.
Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.
For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.
Amarin Corporation (NASDAQ:AMRN) reported record annual revenue of $614.1 million for 2020, up 43% from 2019, with Q4 revenue at $167.3 million, a 17% increase year-over-year. This growth was driven by increased use of VASCEPA® (icosapent ethyl) despite COVID-19 challenges. Amarin received a positive CHMP opinion for VAZKEPA® in Europe, expecting formal approval in April 2021. The company ended 2020 with a strong balance sheet, totaling $563.4 million in cash and no debt. Amarin anticipates robust growth in 2021, particularly in the U.S. and international markets.
Amarin Corporation plc (NASDAQ:AMRN) has announced presentations by CEO John F. Thero at two investor conferences: the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 9:20 a.m. ET, and the Cowen 41st Annual Health Care Conference on March 1, 2021, at 10:20 a.m. ET. Live audio webcasts will be available on Amarin's website for 30 days post-event. Amarin is committed to evolving cardiovascular disease management and has grown significantly since its inception in 2009, now employing approximately 1,000 individuals globally.
Amarin Corporation announces a conference call for discussing its fourth quarter and full year 2020 financial results on February 25, 2021, at 7:30 a.m. ET. This follows the anticipated release of financial results earlier that day. Investors can access the call via the company's website or by dialing the designated phone numbers. A replay will be available for two weeks thereafter. Questions can be submitted prior to the call via email, and management will respond to queries during the live session.
Amarin Corporation plc (NASDAQ:AMRN) announced that its partner Edding has initiated regulatory reviews for VASCEPA® (icosapent ethyl) in Mainland China and Hong Kong. The Chinese National Medical Products Administration has accepted VASCEPA's new drug application, with a decision expected by the end of 2021. Concurrently, Hong Kong's Department of Health is reviewing VASCEPA based on prior approvals in the U.S. and Canada. Both parties aim to provide this treatment option, highlighting its significance in combating cardiovascular disease in the region.
Amarin Corporation (NASDAQ:AMRN) announced a positive opinion from the CHMP of the EMA recommending marketing authorization for icosapent ethyl, branded as VAZKEPA, for reducing cardiovascular event risks in high-risk patients. This decision is based on over a decade of research, including the REDUCE-IT study, which showed a 25% relative risk reduction in major cardiovascular events among patients taking the drug. A European Commission decision is expected within 67 days, potentially granting ten years of market protection in the EU and extending exclusivity into 2039 through pending patents.
Amarin Corporation has expanded its patent infringement lawsuit against Hikma Pharmaceuticals to include Health Net, a health insurance provider, in the U.S. District Court in Delaware. The lawsuit claims Health Net has induced pharmacies to dispense Hikma's generic icosapent ethyl capsules, infringing on Amarin's patents for cardiovascular risk reduction. Amarin seeks a permanent injunction against these practices and monetary damages. The company emphasizes the significance of its patents in preventative cardiovascular care and plans to pursue the case vigorously, leveraging proceeds from VASCEPA sales.
Amarin Corporation plc (NASDAQ:AMRN) announced that icosapent ethyl has been included in the updated Guidelines for Primary Prevention of Cardiovascular Diseases by the Chinese Society of Cardiology (CSC) for 2021. The guidelines recommend icosapent ethyl 2 grams twice daily to reduce atherosclerotic cardiovascular disease (ASCVD) risk, highlighting its efficacy as shown in the REDUCE-IT study. With this inclusion, icosapent ethyl is now recognized by 13 medical associations worldwide. The CSC classification reflects strong evidence, underscoring the importance of this treatment for at-risk patients.
Amarin Corporation plc (NASDAQ:AMRN) announced preliminary unaudited total net revenue for 2020 estimated at $610 million, marking a 42% increase from 2019. This growth was primarily driven by increased prescriptions of VASCEPA® despite COVID-19 challenges. The company ended 2020 with over $550 million in cash and no debt. Amarin is preparing for the regulatory approval of VASCEPA in Europe and aims for a commercial launch in 2021. The company plans to present further details at the J.P. Morgan Healthcare Conference on January 12, 2021.
Amarin Corporation plc has announced that its president and CEO, John F. Thero, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, from 2:00 to 2:40 p.m. Eastern Time. A live audio webcast will be accessible at amarincorp.com for 30 days following the event.
Amarin focuses on cardiovascular health with its lead product, VASCEPA (icosapent ethyl), currently prescribed in the U.S., Canada, Lebanon, and the UAE. The company is pursuing further regulatory approvals in China, Europe, and the Middle East.
Amarin Corporation (NASDAQ:AMRN) presented critical findings related to VASCEPA® (icosapent ethyl) during the National Lipid Association Scientific Sessions 2020. Key highlights include a significant correlation between eicosapentaenoic acid (EPA) levels and improved cardiovascular outcomes, showcasing a 400% increase from baseline in a prominent trial. Additionally, the VASCEPA COVID-19 CardioLink-9 Trial indicated a 25% reduction in high-sensitivity C-reactive protein (hsCRP) among COVID-19 patients, suggesting VASCEPA may help alleviate symptoms while demonstrating good safety and tolerability.
FAQ
What is the current stock price of Amarin Plc (AMRN)?
What is the market cap of Amarin Plc (AMRN)?
What does Amarin Corporation do?
What is VASCEPA®?
How did Amarin perform financially in recent quarters?
What recent strategic initiatives has Amarin undertaken?
What are the key markets for Amarin's products?
What recent achievements have boosted Amarin's market position?
How does VASCEPA® benefit patients?
Who are the key executives at Amarin?
What is the purpose of Amarin's share repurchase plan?
How does Amarin support its global operations?
